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C-fiber sensory afferent neurons, which contain neu­
ropeptides such as calcitonin-gene related peptide 
and substance P, mediate a wide variety of physio­
logic responses, including chemogenic pain, thermo­
regulation, and neurogenic inflammation. Capsaicin, 
the pungent constituent in red pepper, functions to 
activate and then, at higher doses and longer times, 
desensitize this class of neurons. This latter response 
provides the basis for the therapeutic application of 
capsaicin. A major advance in the field has been the 
identification of resiniferatoxin, a phorbol-related 
diterpene, as an analog of capsaicin that is ultrapo­
tent but with differential selectivity. In particular, 
resiniferatoxin is only similar in potency for induc­
tion of pain but is much more effective for desensiti­
zation. Structure-activity analysis in whole animal 
experiments provides further evidence for dissocia­
tion of biologic endpoints, strongly arguing for the 
existence of vanilloid receptor subclasses. Using res-
N atural products afford a window to reveal interest­ing biology, provide the tools to explore tillS biology, and generate leads for its ultimate thera­peutic manipulation. Capsaicin, the pungent con­stituent in red peppers, has numerous acute bio­
logic effects (reviewed in Holzer, 1991). Prominent among these 
are induction of pain, modulation of thermoregulation, and pro­
duction of neurogenic inflammation. These acute responses to 
capsaicin may be followed by desensitization, depending on the 
dose of capsaicin and the duration of exposure. 
The specific responses to capsaicin are believed to be mediated 
by its activation of a subset of sensory neurons, namely those with 
thin unmyelinated (C-fiber) and thin myelinated (AD-fiber) pro­
cesses. Although no exact neurochemical correlation exists, these 
neurons in general contain calcitonin-gene related peptide and 
tachykinins such as substance P. These sensory afferent neurons 
serve both afferent and efferent functions; activation both transmits 
signals to the central nervous system and releases neuropeptides in 
the periphery. 
The accepted mechanism of action for capsaicin is activation of a 
non-voltage-dependent, relatively nonselective cation channel in 
the sensory afferent neurons (Wood et ai, 1988; Oh et ai, 1996). The 
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iniferatoxin, we have been able to define specific. 
high-affinity receptors for capsaicin both in animll 
models such as rats and in man. Of great importance. 
the pharmacologic characterization in cultured dor­
sal root ganglion cells of the high-affinity resinifen­
toxin-binding site and of the physiologic respolIH 
believed to be directly coupled to the receptor. viz. 
calcium uptake, differed in structure-activity and ill 
cooperativity. We conclude that multiple high-affin­
ity vanilloid receptor subclasses mediate vanilloid 
response; moreover, the resiniferatoxin-selective 
subclass of vanilloid receptors is not the voltage­
independent, cation-nonselective ion channel as pre­
viously believed. Optimization of ligands for the 
individual vanilloid receptor subclasses should revo­
lutionize this therapeutic area. Key words: capsald. 
resiniferatoxin. Journal of Investigative Dermatology Syt/I" 
posium PI'oceedings 2:56-60, 1997 
influx of calcium ions through this channel has been believed to bt 
responsible for the subsequent desensitization, and extensive struc· 
ture-activity analysis has been conducted to define the charartem. 
tics of active capsaicin analogs using calcium uptake as the meastllt 
of response (Walpole et aI, 1993a, 1993b, 1993c, 1996). 
Therapeutic Targets for Vanilloids The important physio­
logic roles played by capsaicin-sensitive neurons, together with thr 
ability of capsaicin to desensitize these neurons, has excited grta 
interest in capsaicin and capsaicin analogs as possible therapeutic 
agents (Campbell et ai, 1993). In the cancer field, therapeutic 
targets include drug-induced mucositis, cystitis, emesis, and nn!­
ropathy, post-surgical neuropathy, e.g., post-mastectomy pain, and 
neuropathic cancer pain. Therapeutic targets for topical appliratioa 
to skin include diabetic neuropathy, post-herpetic neuralgia. plOll­
asis, and pruritus (see Table I). Other therapeutic targets inrludr 
vasomotor rhinitis. cluster headache, asthma bronchiale. arthritis. 
and bladder hyperreflexia. Clinical studies have shown encouragq 
results for many of these indications. Unfortunately, the aCUlr 
burning sensation that accompanies initial capsaicin applicatiOll, 
coupled with the necessity for repeated applications, has proved to 
be the linliting toxicity. 
Resiniferatoxin as an Ultrapotent Capsaicin Analog 0' 
tensive structure-activity analysis of capsaicin analogs had failed to 
reveal compounds appreciably more potent than capsaicin ied 
(Szolcsanyi. 1982; Hayes et aI, 1984). A major advance, therefolf, 
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Table I. Topical Capsaicin in Dermatology 
Disease Site of Action References 
Diabetic neuropathy 
Herpes 
Pain, burning sensation Rains and Bryson, 1995 
Infection Dissemination, itching, pain Stanberry et ai, 1992 
Bernstein et aI, 1989 
Darsow et aI, 1996 
Postherpetic neuralgia 
Pruritus circumscriptus sine materia 
Pruritus 
Aquagenic Itching, burning sensation, exfoliation Lotti et aI, 1994 
Vulvar vestibulitis 
Solar (brachioradial) 
Hemodialysis-related 
N otalgia paraesthetica 
Psoriasis Erythema, scaling, pruritus 
Rumsfield and West, 1991 
Knight and Hayashi, 1994 
Breneman et aI, 1992 
Leibsohn, 1992 
Bernstein, 1987 
Ellis et aI, 1993 
Atopic eczema Itching, inflammation, pain 
Kurkccuoglu and Alaybeyi, 1990 
Zhang and Li Wan Po, 1994 
Weisshaar et aI, 1996" 
Inflammation induced by 
Substance P, histamine, PUVA 
Other applications 
Pain, erythema, itching Bjerring and Arendt-Nielsen, 1990 
Burrows and Norris, 1994 
Apocrine chromhidrosis 
Idiopathic cold contact urticaria 
Malignant tumor 
Perspiration, erythema, itching, hyperalgesia, allodynia, 
dysesthetic pain 
Rumsfield and West, 1991 
Husz et aI, 1991 
Wist and Risberg, 1993 
• Weisshaar E, Heyer G, Forster C, Handwerker HO: Effects of topically applied capsaicin in atopic eczema.] Invest DennatoI107:467(115}, 1966 (abstr). 
was the demonstration by this laboratory that resiniferatoxin 
(RTX) , a phorbol-related diterpene, acted as a capsaicin analog 
(Szallasi and Blumberg, 1989). RTX was isolated by Hecker and 
co-workers from the latex of Euphorbia resinifera on the basis of its 
acute irritant activity (Hergenhahn et ai, 1975; Hecker, 1978). 
Although sharing the typical diterpene structnre of the phorbol 
esters and related analogs, RTX differs from typical phorbol 
derivatives by substitution on the primary hydroxyl group (Fig 1). 
A free hydroxyl at this position is required for activity of the 
phorbol esters at their primary target, protein kinase C (Hecker, 
1978), and indeed RTX is inactive as a tumor promoter (zur 
Hausen et ai, 1979), as an inducer of typical phorbol ester responses 
(Driedger and Blumberg, 1980a), or as a ligand for protein kinase 
Phorbol 12,13-dibutyrate 
><D::\ .,.cHO 
�.� ..... 
HO 
Resiniferatoxin 
00r
�
, 
OH 
IsoveIleraI 
Figure 1. Comparison of chemical structures. Phorbol 12,13-dibu­
tyrate is a typical phorbol ester and protein kinase C activator. RTX 
possesses homology both to the phorbol esters and to capsaicin; biologically 
it functions only as a capsaicin analog. Isovelleral, despite the modest 
structural similarity to capsaicin, acts as a capsaicin analog. 
C (Driedger and Blumberg, 1980b). In contrast, the presence of the 
homovanillyl ester was shown to be essential for the unique irritant 
activity of RTX (Szolcsanyi and J ancso-Gabor, 1975; Szallasi et ai, 
1989a). Motivated by the homology between the homovanillyl 
ester of RTX and the vanillylamide moiety of capsaicin, we 
examined possible similarities in the biologic activities of these two 
classes of compounds. 
RTX, like capsaicin, caused chemogenic pain, hypothermia, and 
neurogenic inflammation upon acute administration to rats (Szallasi 
and Blumberg, 1989). For induction of pain it was several fold more 
potent than capsaicin; for hypothermia and neurogenic inflamma­
tion it was 3 to 4 orders of magnitude more potent. Capsaicin at 
higher doses and longer times causes desensitization. RTX likewise 
caused desensitization to itself and cross-desensitization to capsa­
icin. Once again, RTX was orders of magnitude more potent for 
desensitization than was capsaicin. Interestingly, whereas RTX was 
relatively less potent for inducing pain than for inducing hypother­
mia or neurogenic inflammation, RTX was more potent for 
desensitization of pain than for desensitization of the other re­
sponses (Szallasi and Blumberg, 1989). The duration of this desen­
sitization is impressive. Application of a single, maximally tolerated 
dose ofRTX fully abrogated the pain response to capsaicin for 21 d 
(Szallasi et ai, 1989b); longer times were not examined. The 
duration of the desensitization depended on the specific biologic 
response examined. Not only was the potency ofRTX for desen­
sitization of pain greater than that for desensitization of neurogenic 
inflammation, the other response evaluated, but the duration of the 
desensitization was longer (Szallasi et ai, 1989b). 
Only limited structure-activity analysis ofRTX analogs has been 
carried out for various biologic endpoints. Nonetheless, these early 
results suggest marked potential to dissect subclasses of response 
through medicinal chemistry. Tinyatoxin induces very little re­
sponse in the eye-wiping assay for chemogenic pain (Szallasi et ai, 
1991). 12-DeoxyphorboI13-phenylacetate 20-homovanillate failed 
to induce hypothermia at the EDso for desensitizing neurogenic 
inflammation (Szallasi et ai, 1989a); RTX, conversely, was an order 
of magnitude more potent for the former than for the latter 
response (Szallasi and Blumberg, 1989). This dissociation of bio­
logic responses is not limited to vanilloids of the RTX class but is 
also true for capsaicin analogs. For example, relative to capsaicin, 
olvanil is more elfective for desensitization than for induction of 
pain (Dickenson et ai, 1990; Dray et ai, 1990). 
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Although it is clear that di1ferences in phannacokinetics may 
complicate analysis (Maggi et aI, 1990), the �os� straightforw�d 
interpretation is that distinct subclasses of vanillold receptors WIth 
distinct phannacology mediate subsets of responses. Moreover, the 
selectivity of RTX for desensitization and of capsaicin for induction 
of pain suggests that di1ferent subclasses in particular may be 
involved in these two sets of responses. 
Characterization of Vanilloid Receptors Using fH]RTX 
Identification of specific receptors for capsaicin had proved prob­
lematic, reflecting the high lipophilicity and moderate (high nano­
molar to low micromolar) potency of capsaicin. Although RTX is 
also lipophilic, its enhanced potency relative to capsaicin pe�tted 
the demonstration of specific vanilloid receptors (Szallasl and 
Blumberg, 1990, 1991). Receptor analysis was further improved by 
exploiting our finding that aI-acid glycopr?tein was a bin�g 
protein for RTX (among other hydrophobIc �omp�unds) WI?t 
micromolar affinity (Szallasi et aI, 1992). By mcluding aI-aCId 
glycoprotein in the wash solution after specific RTX binding had 
reached equilibrium, we were able to extract much of the RTX 
nonspecifically partitioned into membranes (Szalla�i et aI, 19?2). 
Specific binding was found in dorsal root gan�a (Sz�asl et aI, 
1993a), as well as in their axons, central processes m lammae I and 
II of the dorsal horn of the spinal cord, and in the periphery (Acs et 
aI, 1994a). The Kd for RTX was approximately 24 pM. The Bmax 
was 85 finol/mg, and the binding reflected positively cooperative 
kinetics with a Hill coefficient of 1.7 (Szallasi et aI, 1993a). The 
characteristics of this specific binding were consistent with those 
expected for a vanilloid receptor. It showed appropriate structure­
activity relations, as well as appropriate tissue and species distribu­
tion. Binding characteristics of [3H]RTX were basically similar for 
the human as for the rat, except that the affinity was somewhat 
lower (Acs et aI, 1994b). 
In addition to the effects of capsaicin on sensory afferent neurons 
of the dorsal root ganglia, capsaicin also has central effects, in 
particular on thermoregulation. We thus exantined brains from 
both rats and humans for specific RTX binding. In both, we were 
able to demonstrate specific binding with restricted regional local­
ization (Acs et aI, 1996a). Binding was highest in the preoptic area, 
locus ceruleus, and medial hypothalamus, all of which are brain 
regions implicated in capsaicin actions. Although we were unable 
to deterntine the kinetic constants for the brain binding because of 
insufficient material, the data suggested that the binding affinities 
were lower than in the dorsal root ganglia or spinal cord, consistent 
with a distinct subclass of receptors in the central nervous system. 
Further evidence for receptor subclasses is provided by the 
analysis of specific RTX binding in some peripheral tissues, in 
particular in airways (Szallasi et aI, 1993b) and colon (Goso et aI, 
1993). This binding showed lower affinity for RTX and noncoop­
erative kinetics. In addition, it showed a shifr in structure-activity 
relations; capsaicin and the antagonist capsazepine inhibited bind­
ing with higher affinity than in dorsal root ganglion membranes. 
The initial interpretation was that peripheral receptors di1fered from 
those in the cell bodies or central processes of the dorsal root 
ganglion neurons. Unfortunately, it is now evident t�at . assay conditions can affect binding characteristics. Thus, RTX bmding to 
bladder was either similar to that in dorsal root ganglion neurons 
(Acs et aI, 1994a) or not (Szallasi et aI, 1993c), depen�g on the 
assay conditions. Likewise, RTX binding to human spmal cord 
membranes differed in affinity and cooperativity, depending on the 
study (Acs et aI, 1994b; Szallasi and Goso, 1994). N onetheless, �e 
demonstration of vanilloid responses in intact dorsal root ganglion 
neurons with similar phannacology to that found in airways (see 
below) now provides support for the analysis of RTX binding in 
this tissue. A plausible interpretation is that this lower affinity RTX 
binding may be obscured in tissues also containing the higher 
affinity receptor. 
Relationship between [3H]RTX Binding and 4SCa Uptake in 
DRG Neurons The conclusion from the analysis of eH]RTX 
binding in membrane preparations was that the binding reflected 
JID SYMPOSIUM PROCEEDINGS 
Table II. Comparison ofR-Type and C-Type Vanilloid 
Receptors" 
RTX, Kd 
Capsaicin, � 
Cooperativity 
Ruthenium Red sensitivity 
Ca + + uptake stimulation 
Desensitization 
Toxicity upon desensitization 
R-type 
39 pM 
4900nM 
1.5-2.0 
14nM 
No 
Yes 
No 
C-type 
940 pM 
270nM 
0.9-1.2 
790nM 
Yes 
Yes 
• From Acs G, Biro T, Acs P, Modarres S, Blumberg PM, submitted for publication. 
the appropriate tissue, species, and structure-activity relations to 
represent the vanilloid receptor. Twin weaknesses of the comp�­
ison, however, were the uncertainties introduced by phannacoki­
netics in the biologic studies and the unknown distortions in 
receptor properties upon membrane preparation. In addition, the 
biologic evidence for the existence of multiple subclasses of 
receptors clearly argued that the binding analysis, revealin� � single 
receptor, was incomplete. The development of assay conditIons for 
eH]RTX binding in intact cultured dorsal root ganglion neurons 
has permitted these issues to begin to be addressed (Acs et aI, 
1996b). In fact, [3H]RTX binding in the intact rat dors� root 
ganglion cells showed similar characteristics to those found m our 
membrane preparations. We obtained similar � values, compara­
ble B values, and similar structure-activity relations. Of great 
impo;;'ce, we were able to compare direcdy binding and biologic 
response in these cells. 
The biologic response that we exantined was Ca2+ uptake 
because this response measures ionic flux through the nonspecific 
cation channel that had been suggested to represent the receptor. A 
very significant observation was that neither the absolute affini�es 
of the ligands nor the structure-activity relations for high-affinity 
[3H]RTX binding and for Ca2+ uptake matched (Acs et aI, 1996b). 
Rather, one subset of ligands, exemplified by RTX and by 
tinyatoxin, displayed higher affinity for displacement of [3H]RTX 
binding than for induction of Ca2+ uptake. Conversely, an0?ter 
subset of ligands, exemplified by capsaicin and by capsazepme, 
displayed the opposite preference-higher affinity for the Ca2+ 
uptake site than for displacement of [3H]RTX binding. A further 
di1ference between the two sites was cooperativity. Whereas the 
[3H]RTX binding showed positive cooperativity with a Hill coef­
ficient of close to 2, d!at for Ca2+ uptake was noncooperative, wid! 
a Hill coefficient of approximately 1. 
The absolute di1ference in ligand selectivity between the two 
sites was impressive. In particular, whereas the relative potency for 
binding versus Ca2+ uptake yielded a ratio (K/EDso) of 0.041 for 
RTX, the corresponding ratio for capsaicin was 14.5. Thus, the 
selectivity of RTX for displacement of the high-affinity [3H]RTX 
binding versus stimulation of Ca2+ uptake was 350 compared to 
capsaicin. Interestingly, di1ferences in potencies of ligands for 
displacement of [3H]RTX binding and for induction of Ca2+ 
uptake had also been observed by others using particula�e prepa­
rations for the binding assays (Walpole et aI, 1996). The di1ferences 
had been ascribed, however, to distortions caused by the di1ferent 
methodologies (Walpole et aI, 1996). 
We conclude, in contrast, d!at the two sites define di1ferent 
subclasses of vanilloid receptors, which we will refer to as the 
R(TX)-type and C(apsaicin)-type (Table II.). A further very 
important conclusion from these observations is that the R-type 
vanilloid receptor is not the well characterized non-voltage-depen­
dent nonselective cation channel that had been described previ­
ously. Rather, the R-type vanilloid receptor has some other 
function, perhaps as a metabotropic receptor. The vanilloid recep­
tors thus may join other classes of receptors, e.g., glutamate or 
cholinergic receptors, wid! bod! ionotropic and metabotropic sub­
types. 
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As yet, we have not succeeded in demonstrating a low(er) affinity 
binding site for [3H]RTX corresponding to the C-type receptor in 
the dorsal root ganglion cells. Because the binding affinity should be 
25-fold lower (and the nonspecific binding at the Kd correspond­
ingly 25-fold higher) than for the R-type receptor, we presume that 
the specific binding is obscured by the nonspecific background. It is 
interesting to note, however, that the binding of RTX to rat 
airways shows similar affinity and lack of cooperativity to that found 
for the C-type receptor (Szallasi et ai, 1993b), albeit some other 
characteristics differ. 
R-Type Vanilloid Receptors, Like C-Type Receptors, Me­
diate Desensitization Because Ca2+ uptake via the C-type 
receptor has been considered to mediate the actions of capsaicin on 
sensory a1ferent neurons, what is the fimction of the R-type 
vanilloid receptor? Based on the biologic results in the intact rat, for 
which RTX is di1ferentially effective for desensitization and di1fer­
entially ineffective for induction of chemogenic pain, a plausible 
hypothesis was that the R-type vanilloid receptor mediates desen­
sitization. In fact, pre-treatment of cultured dorsal root ganglion 
cells with RTX inhibited subsequent stimulation ofCa2+ uptake in 
response to capsaicin challenge (Acs G, Biro T, Acs P, Modarres S, 
Blumberg PM, submitted for publication). Partial inhibition was 
observed within 30 min ofRTX pre-treatment, with maximal effect 
attained by 5 h. The EDso for desensitization, 81 ± 5 pM, was 
similar to that for binding to the R-type receptor, 47 ± 4 pM, and 
the dose-response curve displayed cooperativity, with a Hill coef­
ficient of 1.51, once again consistent with interaction at the R-type 
receptor. 
The inhibition of Ca2+ uptake behaved as expected for desensi­
tization induced by the R TX pre-treatment rather than for com­
petition at the C-type receptor. First, the extent of the inhibition 
and the EDso for RTX in the pre-treatment were independent of 
the identity of the specific ligand, capsaicin or RTX, used to induce 
the Ca2+ uptake. Second, the desensitization was independent of 
the concentration of the challenging dose of ligand used to induce 
the Ca2+ uptake. Finally, the desensitization was unaffected by 
washing the cells after the pre-treatment to remove the RTX. 
The identification of a biologic response, viz. desensitization, for 
the R-type vanilloid receptor has permitted further di1ferentiation 
of the properties of the R- and C-type receptors (Acs G, Biro T, 
Acs P, Modarres S, Blumberg PM, submitted for publication). 
Ruthenium red has been reported to be a noncompetitive vanilloid 
antagonist, interfering with Ca2+ binding. Ruthenium red blocked 
Ca2+ uptake induced by capsaicin with an EDso of 790 nM. 
Ruthenium red also blocked the desensitization response to RTX, 
but with a 60-fold higher potency, viz. 14 nM. These results 
suggest some role for Ca2+ in the desensitization, although through 
a different site than the nonselective ion channel. 
Occupancy of the C-type receptor also causes desensitization 
(Acs G, Biro T, Acs P, Modarres S, Blumberg PM, submitted for 
publication). If cells are pre-treated with capsaicin, desensitization 
of Ca2+ uptake to subsequent vanilloid challenge occurs with an 
EDso corresponding to that for induction of the initial Ca2+ uptake. 
The characteristics of this latter desensitization behavior are still 
being determined, but, based on the known ability of capsaicin to 
cause loss of cell viability consequent to Ca2+ uptake (reviewed in 
Holzer, 1991), presumably reflect cell toxicity. 
Implications of Vanilloid Receptor Subtypes The conclu­
sion that distinct pathways for vanilloid desensitization are medi­
ated by separate receptors has implications of great importance for 
development of therapeutic agents. First, Ca2+ uptake has been 
used as the central endpoint for evaluating structure-activity rela­
tions at "the vanilloid receptor" (Walpole et ai, 1993a, 1993b, 
1993c). We now understand that it is crucial to evaluate in parallel 
the structure-activity relations for [3H]RTX binding. Ligands of 
particular interest for desensitization may be those selective for R­
versus C-type receptors. Second, the biologic correlates for these 
two receptor subclasses, and particularly the desensitization behav­
ior at the whole anirnal level corresponding to these two receptor 
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classes, urgently require identification. It has long been recognized 
that desensitization/ defimctionalization at the whole anirnal level is 
highly complex and dose dependent (Holzer, 1991); distinct path­
ways of desensitization may help to rationalize this complexity. 
Third, antagonists of vanilloid action have been identified (Amann 
and Maggi, 1991; Bevan et ai, 1992), but they have failed so far to 
find a therapeutic niche. Combination of a C-type selective va­
nilloid antagonist with a R-type selective agonist should yield greater 
selectivity than that attainable with the R-type selective agonist 
alone. The utility of this approach is illustrated with capsazepine, 
the best characterized vanilloid antagonist. In the rat, capsazepine 
has a K; of 290 nM for Ca2+ uptake compared to a K; of 3700 nM 
for desensitization (Acs et ai, submitted for publication). As de­
scribed above, RTX affords a 350-fold improvement compared to 
capsaicin in selectivity for desensitization mediated through the 
R-type receptor versus Ca2+ uptake. In the presence of capsazepine, 
this ratio approaches 4,500. 
Novel Structural Classes ofVanilloids Driven by the identi­
fication of RTX as an ultrapotent capsaicin analog with a unique 
pattern of biology, our understanding of vanilloid receptors has 
improved greatly. A complementary area of great interest is the 
identification of novel structural classes of vanilloids. The mush­
room Lactarius vellereus is the source of the pungent terpenoid 
isovelleral (Fig 1). Related terpenoids, containing a characteristic 
unsaturated dialdehyde motif, have been isolated from a variety of 
natural sources (Sterner et ai, 1985; Anke and Sterner, 1991). 
Because of their reactive nature, these compounds would be 
expected to interact with a variety of targets. We find that the 
vanilloid receptor is one of these targets, presumably mediating its 
pungency (Szallasi et ai, 1996). Thus, isovelleral is pungent on the 
human tongue, blocks [3H]RTX binding with an affinity of 5 J.LM, 
and stimulates Ca2+ uptake with an EDso of 95 nM. These values 
argue that isovelleral is more potent than capsaicin. They further 
indicate that isovelleral is markedly selective for the C-type recep­
tors. Because of its reactive nature, the role of pharmacokinetics in 
the behavior of isovelleral remains to be fully evaluated. In any 
case, incorporation of the unsaturated dialdehyde motif into the 
design of selective vanilloids may afford interesting opportunities 
for therapeutic development. 
Future Prospects The vanilloid field is particularly ripe for 
therapeutic advance. Using capsaicin, therapeutic targets have been 
defined and their validity proved, at least in principle. Unfortu­
nately, the limited therapeutic index for capsaicin has limited its 
utility. The rapid progress in defining vanilloid receptors, in 
describing receptor isotypes with distinct mechanisms and fimc­
tions, and in broadening our understanding of vanilloid structure­
activity relations promises a marked impact on these therapeutic 
applications. 
A major unsolved frontier remains the identification of endoge­
nous vanilloids. The picomolar affinity of RTX strongly predicts 
their existence, in analogy with the enkephalins as endogenous 
opiates. Indirect support for the existence of endogenous vanilloids 
has been recently provided by the preliminary report that the 
capsaicin antagonist capsazepine blocks Fos labeling of spinal cord 
neurons in response to experimental inflammation in the paw of the 
rat.1 In light of the dramatic effects of capsaicin on inflammation, 
pain, and thermoregulation, endogenous vanilloids may be physi­
ologic mediators of great significance. 
REFERENCES 
Acs G, Palkovits M, Blumberg PM: Comparison of [3H]resiniferatoxin binding by the 
vanilloid (capsaicin) receptor in dorsal root ganglia, spinal cord, dorsal vagal 
complex, sciatic and vagal nerve and urinary bladder of the rat. Life Sd 
55:1017-1026, 1994a 
1 lung Yl, Kwak lY, Park Y-S, Kim K-l, Oh U: Evidence that 
endogenous capsaicin-like substance is involved in generating inHammatory 
pain. 26th Annual Meeting of the Society for Neuroscience 22:876, 1996 (abstr). 
60 BIRO ET AL 
Acs G, Palkovits M, Blumberg PM: ['HJresiniferatoxin binding by the human vanilloid 
(capsaicin) receptor. Mol Brain Res 23:185--190, 1994b 
Acs G, Palkovits M, Blumberg PM: Specific binding of ['H]resiniferatoxin by human 
and rat preoptic area, locus ceruleus, medial hypothalamus, reticular formation, 
and ventral thalamus membrane preparations. Life Sci 59:1899-1908, 1996a 
Acs G, Lee J, Marquez VE, Blumberg PM: Distinct structure-activity relations for 
stimulation of "Ca uptake and for high affinity binding in cultured adult rat 
dorsal root ganglion neurones and dorsal root ganglion membranes. Mol Brain Res 
35:173-182, 1996b 
Amann R, Maggi CA: Ruthenium red as a capsaicin antagonist. Life Sci 49:849- 856, 
1991 
Anke H, Sterner 0: Comparison of the antimicrobial and cytotoxic activities of twenty 
unsaturated sesquiterpene dialdehydes from plants and mushrooms. Plallta Med 
57:344-346, 1991 
Bernstein JE: Capsaicin in the treatment of dermatologic disease. Cutis 39:352-353, 
1987 
Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE: Topical capsaicin 
treatment of chronic postherpetic neuralgia.] Alii Acad Dermatol 21 :265-270, 
1989 
Bevan SJ, Hothi S, Hughes IF, Rang HP, Shah K, Walpole CSJ, Yeats JC: 
Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. 
Br] PharmacoI107:544-552, 1992 
Bjerring P, Arendt-Nielsen L: Inhibition of histamine skin flare reaction following 
repeated topical applications of capsaicin. Allergy 45:121-125, 1990 
Breneman DL, Cardone JS, Blumsack RF, Lather RM, Searle EA, Pollack VE: Topical 
capsaicin for treatment of hemodialysis-related pruritus. ] Am Acad Dermatol 
26:91-94, 1992 
Burrows NP, Norris PG: Treatment of PUV A-induced skin pain with capsaicin. Br] 
DfTlllatol 131:584-585,1994 
Campbell E, Bevan S, Dray A: Clinical applications of capsaicin and analogs. In: Wood 
IN (ed) Capsaicin ill the Study rifPain. Academic Press, London, 1993, pp 255-272 
Darsow V, Lorenz J, Bromm B, Ring]: Pruritus circumscriptus sine materia: a sequel 
of postzosteric neuralgia. Evaluation by quantitative psychophysical examination 
and laser-evoked potentials. Acta Derm VellfTeol (Stock") 76:45-47, 1996 
Dickenson A, Hughes C, Rueif A, Dray A: A spinal mechanism of action is involved 
in the antinociception produced by the capsaicin analogue NE 19550 (olvanil). 
Pain 43:353-362, 1990 
Dray A, Bettaney J, Rueif A, Walpole CSJ, Wrigglesworth R: NE-19550 and 
NE-21610, antinociceptive capsaicin analogues: studies on nociceptive fibres of 
the neonatal tail in vitro. Eur] PharmacoI181:289-293, 1990 
Driedger PE, Blumberg PM: Diiferent biological targets for resiniferatoxin and phorbol 
12-myristate 13-acetate. Cancer Res 40:1400-1404, 1980a 
Driedger PE, Blumberg PM: Specific binding of phorbol ester tumor promoters. Proc 
Natl Acad Sci USA 77:567-571, 1980b 
Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, Prawer S, Krueger 
G, Rex IH Jr, WolfJE: A double-blind evaluation of topical capsaicin in pruritic 
psoriasis comments.] Am Acad Dermatol 29:438-442, 1993 
Goso C, Evangelista S, Tramontana M, Manzini S, Blumberg PM, Szallasi A: Topical 
capsaicin administration protects against trinitrobenzene sulfuric acid (TNB)­
induced colitis in the rat: characterization of the vanilloid (capsaicin) receptor 
involved. Eur] PharmacoI249:185-190, 1993 
Hayes AG, Oxford A, Reynolds M, Shingler AH, Skingle M, Smith C, Tyers MB: The 
eifects of a series of capsaicin analogues on nociception and body temperature in 
the rat. Life Sci 26:1241-1248, 1984 
Hecker E: Structure-activity relationships in diterpene esters irritant and cocarcino­
genic to mouse skin. In: Siaga TJ, Sivak A, Boutwell RK (eds.) Carcinogenesis, 
Mechanism of Tumor Promotion and Cuearcinogenesis. Vo!' 2. Raven Press, New 
York, 1978, pp 11-48 
Hergenhahn M, Adolph W, Hecker E: Resiniferatoxin and other esters of novel 
polyfnnctional diterpenes from Enphorbia resinifera and unispina. Tetrahedron Lett 
19:1595--1598, 1975 
Holzer P: Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin 
sensory neurons. Pharmacol Rev 43:143-200, 1991 
Husz S, Toth-Kasa I, Obal F, Jancso G: A possible pathomechanism of the idiopathic 
cold contact urticaria. Acta PI'ysiol Hung 77:209-215, 1991 
Knight TE, Hayashi T: Solar (brachioradial) pruritus - response to capsaicin. Int] 
DfTlllatol 33:206-209, 1994 
Leibsohn E: Treatment of notalgia paresthetica with capsaicin. Cutis 49:335--336, 1992 
Lotti T, Teofoli P, Tsampau 0: Treatment of aquagenic pruritus topical with capsaicin 
cream.] Am Acad DfTlllatol 30:232-235, 1994 
Maggi CA, Patacchini R, Tramontana M, Amann R, Giuliani S, Santicioli P: 
Similarities and diiferences in the action of resiniferatoxin and capsaicin on central 
and peripheral endings of primary sensory neuroDS. Neuroscience 37:531-539, 
1990 
Oh V, Hwang SW, Kim 0: Capsaicin activates a nonselective cation channel in 
cultured neonatal rat dorsal root ganglion neurons.] Neurosci 16:1659-1667, 
1996 
Rains C, Bryson HM: Topical capsaicin. A review of its pharmacological properties 
JID SYMPOSIUM PROCEEDINGS 
and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and 
osteoarthritis. Drugs Aging 7:317-328, 1995 
Rumsfield JA; West DP: Topical capsaicin in dermatologic and peripheral pain 
disorders. DICP 25:381-387, 1991 
Stanberry LR, Bourne N, Bravo FJ, Bernstein 01: Capsaicin-sensitive peptidergic 
neurons are involved in the zosteriform spread of herpes simplex virus infection. 
] Med Virol 38:142-146,1992 
Sterner 0, Bergman R, Kihlberg J, Wickberg B: The sesquiterpenes of Lactarius 
vellereus and their role in the proposed chemical defense system.] Nat Prod 
48:279 -288, 1985 
Szallasi A, Blumberg PM: Resiniferatoxin, a phorbol-related diterpene, acts as an 
ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neurosciell" 
30:515--520, 1989 
Szallasi A, Blumberg PM: Specific binding of resiniferatoxin, an ultrapotent capsaicin 
analog, by dorsal root ganglion membranes. Brain Res 524:106-111, 1990 
SzaUasi A, Blumberg PM: Characterization of vanilloid receptors in the dorsal hom of 
pig spinal cord. Brain Res 547:335--338, 1991 
Szallasi A, Goso C: Characterization by ['HJresiniferatoxin binding of a human 
vanilloid (capsaicin) receptor in post-mortem spinal cord. Neurosci Lett 165:101-
104, 1994 
Szallasi A, Sharkey NA, Blumberg PM: Structure/activity analysis of resiniferatoxin 
analogs. Pl.ytother Res 3:253-257, 1989a 
Szallasi A, Joo F, Blumberg PM: Duration of desensitization and ultrastructural 
changes in dorsal root ganglia in rats treated with resiniferatoxin, an ultrapotent 
capsaicin analog. Braill Res 503:68-72, 1989b 
Szallasi A, Szolcsanyi J, Szallasi Z, Blumberg PM: Inhibition of ['HJresiniferatoxin 
binding to rat dorsal root ganglion membranes as a novel approach in evaluating 
compounds with capsaicin-like activity. NauIIY" Schmiedeberg's Arch Pharmacol 
344:551-556,1991 
Szallasi A, Lewin NA, Blumberg PM: Identification of alpha-1-acid glycoprotein 
(orosomucoid) as a major vanilloid binding protein in serum.] Pharmacol Exp Ther 
262:883-888, 1992 
Szallasi A, Lewin NA, Blumberg PM: Vanilloid (capsaicin) receptor in the rat: positive 
cooperativity of resiniferatoxin binding and its modulation by reduction and 
oxidation.] Pharmacol Exp Ther 266:678-683, 1993a 
Szallasi A, Goso C, Blumberg PM, Manzini S: Competitive inhibition by capsazepine 
of['H]resiniferatoxin binding to central (spinal cord and dorsal root ganglia) and 
peripheral (urinary bladder and airways) vanilloid (capsaicin) receptors in the rat. 
] Pharmacol Exp Ther 267:728-733, 1993b 
Szallasi A, Conte B, Goso C, Blumberg PM and Manzini S: Characterization of a 
peripheral vanilloid (capsaicin) receptor in the urinary bladder of the rat. Life Sci 
52:221-226, 1993c 
Szallasi A, Jonassohn M, Acs G, Biro T, Acs P, Blumberg PM, Sterner 0: Pnngent 
terpenoids possessing an unsaturated 1,4-dialdehyde moiety stimulate capsaicin­
sensitive neurons in a vanilloid receptor-mediated fashion. Br ] Pharmacol 
119:283-290, 1996 
Szolcsanyi J, Jancso-Gabor A: Sensory eifects of capsaicin congeners. I. Relationship 
between chemical structure and pain-producing potency of pungent agents. 
Arzneimitte!{orschung 25:1877-1881,1975 
Szolcsanyi J: Capsaicin type pungent agents producing pyrexia. In: Milton AS (ed.) 
Handbook of Experimental Pharmacology. Vo!' 60. Springer Verlag, Berlin, 1982, pp 
437-478 
Walpole CSJ, Wrigglesworth R, Bevan S, Campbell E, Dray A, James IF, Perkins 
MN, Reid OJ, Winter J: Analogues of capsaicin with agonist activity as novel 
analgesic agents: structure-activity studies. 1. The aromatic "A-region".] Med 
Chen. 36:2362-2372, 1993a 
Walpole CSJ, Wrigglesworth R, Bevan S, Campbell E, Dray A, James IF, Masdin KJ, 
Perkins MN, Winter J: Analogues of capsaicin with agonist activity as novel 
analgesic agents: structure-activity studies. 2. The amide bond "B-region".] Med 
Chem 36:2373-2380, 1993b 
Walpole CSJ, Wrigglesworth R, Bevan S, Campbell E, Dray A,James IF, Masdin KJ, 
Perkins MN, Winter J: Analogues of capsaicin with agonist activity as novel 
analgesic agents: structure-activity studies. 3. The hydrophobic side-chain "C­
region."] Med Chem 36:2391-2389, 1993c 
Walpole CSJ, Bevan S, Bloomfield G, Breckenridge R, James IF, Ritchie T, Szallasi 
A, Winter J, Wrigglesworth R: Similarities and diiferences in the structure­
activity relationships of capsaicin and resiniferatoxin analogues.] Med Chem 
39:2939-2952, 1996 
Wist E, Risberg T: Topical capsaicin in treatment of hyperalgesia, allodynia and 
dysesthetic pain caused by malignant tumour infiltration of the skin. Acta Oncol 
32:343, 1993 
Wood IN, Winter J, James IF, Rang HP, Yeats J, Bevan S: Capsaicin-induced ion 
fluxes in dorsal root ganglion cells in culture.] Neurosci 8:3208-3220, 1988 
Zhang WY, Li Wan Po A: The eifectiveness of topically applied capsaicin. A 
meta-analysis. Eur] Clin Pharmacol 46:517-22, 1994 
zur Hausen H, Bomkamm GW, Schmidt RJ, Hecker E: Tumor initiators and 
promoters in the induction of Epstein-Barr virus. Proc Natl Acad Sci USA 
76:782-785, 1979 
